Pdl Biopharma Inc (PDLI)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 06-2009 | 03-2009 | 12-2008 | 09-2008 | 06-2008 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 174,433 | 174,723 | 132,527 | 555,311 | 476,614 |
| Marketable Securities | 18,269 | N/A | 15,000 | N/A | 13,819 |
| Receivables | 150 | 624 | 13,500 | N/A | N/A |
| Income taxes - deferred | 12,489 | 12,689 | 17,996 | N/A | N/A |
| Other current assets | 0 | 18,469 | 0 | 0 | 0 |
| TOTAL | $207,741 | $208,197 | $180,681 | $571,670 | $503,013 |
| Non-Current Assets | |||||
| PPE Net | 239 | 269 | 1,123 | 127,269 | 130,863 |
| Investments And Advances | 0 | 4,668 | 0 | 0 | 0 |
| Intangibles | 0 | 0 | 0 | 7,821 | 8,232 |
| Other Non-Current Assets | 9,915 | 5,931 | 9,338 | 11,483 | 12,003 |
| TOTAL | $10,154 | $10,868 | $10,461 | $146,573 | $151,098 |
| Total Assets | $217,895 | $219,065 | $191,142 | $718,243 | $654,111 |
| Liabilities | |||||
| Current Liabilities | |||||
| Short Term Debt | N/A | N/A | N/A | 819 | 777 |
| Accounts payable and accrued liabilities | 0 | 51 | 1,717 | 3,478 | 1,862 |
| Accrued Expenses | 5,702 | 2,941 | 12,290 | 17,405 | 16,500 |
| TOTAL | $67,677 | $129,164 | $31,513 | $68,514 | $63,966 |
| Non-Current Liabilities | |||||
| Deferred Revenues | N/A | N/A | 100 | 12,156 | 8,196 |
| Other Non-Current Liabilities | 455,700 | 510,698 | 510,698 | 532,944 | 537,057 |
| TOTAL | $457,200 | $512,198 | $512,198 | $583,356 | $563,045 |
| Total Liabilities | $524,877 | $641,362 | $543,711 | $651,870 | $627,011 |
| Shareholders' Equity | |||||
| Shares Outstanding, K | 119,507 | 119,468 | 119,432 | 119,507 | 119,422 |
| Common Shares | 1,194 | 1,194 | 1,193 | 1,194 | 1,194 |
| Retained earnings | -408,264 | -485,501 | -522,958 | -563,597 | -619,290 |
| Other shareholders' equity | 0 | 0 | 0 | -484 | -465 |
| TOTAL | $-306,982 | $-422,297 | $-352,569 | $66,373 | $27,100 |
| Total Liabilities And Equity | $217,895 | $219,065 | $191,142 | $718,243 | $654,111 |